³Ô¹Ï±¬ÁÏ

Skip to content
Contact Sales 866-417-3024

Regions

North America

Europe

EN | DE | ES | FR | IT

°ä³ó¾±²Ô²¹&²Ô²ú²õ±è;Öйú

´³²¹±è²¹²Ô&²Ô²ú²õ±è;ÈÕ±¾

Asia Pacific

Korea

Latin America

PORTUGUESE | SPANISH

Industries

Life Sciences

MedTech

³Ô¹Ï±¬ÁÏ Logo
  • ³Ô¹Ï±¬ÁÏ
    • Clinical Solutions
      • ³Ô¹Ï±¬ÁÏ Development Cloud
      • ³Ô¹Ï±¬ÁÏ Clinical Platform
      • Clinical Operations
      • ³Ô¹Ï±¬ÁÏ eTMFStay inspection ready
      • ³Ô¹Ï±¬ÁÏ CTMSManage trials end-to-end
      • ³Ô¹Ï±¬ÁÏ PaymentsPay clinical research sites faster
      • ³Ô¹Ï±¬ÁÏ Study StartupAccelerate site activation
      • ³Ô¹Ï±¬ÁÏ RTSMRandomization and supply management
      • ³Ô¹Ï±¬ÁÏ Site ConnectAutomate information sharing
      • ³Ô¹Ï±¬ÁÏ Study TrainingStreamline and automate training
      • ³Ô¹Ï±¬ÁÏ DisclosuresCentralize clinical trial disclosures
      • ³Ô¹Ï±¬ÁÏ OpenData ClinicalProvide investigator and site data
      • Clinical Data
      • ³Ô¹Ï±¬ÁÏ EDCCollect and verify site data
      • ³Ô¹Ï±¬ÁÏ DQSAggregate and clean study data
      • ³Ô¹Ï±¬ÁÏ eCOACapture patient data
      • Patient Experience
      • Vault Platform
      • ³Ô¹Ï±¬ÁÏ Connections Hub
    • Regulatory Solutions
      • ³Ô¹Ï±¬ÁÏ Development Cloud
      • ³Ô¹Ï±¬ÁÏ RIM
      • ³Ô¹Ï±¬ÁÏ RegistrationsTrack global registrations
      • ³Ô¹Ï±¬ÁÏ SubmissionsPlan and manage submissions
      • ³Ô¹Ï±¬ÁÏ Submissions PublishingPublish to health authorities
      • ³Ô¹Ï±¬ÁÏ Submissions ArchiveAccess submissions history
      • Vault Platform
      • ³Ô¹Ï±¬ÁÏ Connections Hub
    • Safety Solutions
      • ³Ô¹Ï±¬ÁÏ Development Cloud
      • ³Ô¹Ï±¬ÁÏ Safety Suite
      • ³Ô¹Ï±¬ÁÏ SafetyAdverse Event management
      • ³Ô¹Ï±¬ÁÏ SafetyDocsManage safety content
      • ³Ô¹Ï±¬ÁÏ Safety WorkbenchAdvanced reporting and analysis
      • ³Ô¹Ï±¬ÁÏ Safety SignalSignal detection and management
      • Vault Platform
      • ³Ô¹Ï±¬ÁÏ Connections Hub
    • Quality Solutions
      • ³Ô¹Ï±¬ÁÏ Quality Cloud
      • Quality Assurance
      • ³Ô¹Ï±¬ÁÏ QMSManage all quality processes in one place
      • ³Ô¹Ï±¬ÁÏ QualityDocsGain control of GxP documents
      • ³Ô¹Ï±¬ÁÏ Validation ManagementManage and execute paperless validation
      • ³Ô¹Ï±¬ÁÏ Batch ReleaseSpeed release decisions with confidence
      • ³Ô¹Ï±¬ÁÏ Product SurveillanceSimplify postmarket surveillance for medical devices
      • ³Ô¹Ï±¬ÁÏ Station ManagerDeliver right content to the right station
      • Training
      • ³Ô¹Ï±¬ÁÏ TrainingEnsure role-based qualification and compliance
      • Quality Control
      • ³Ô¹Ï±¬ÁÏ LIMSOptimize QC labs to increase efficiency
      • Health and Safety
      • ³Ô¹Ï±¬ÁÏ EHSManage environmental, health, and safety processes
      • Contract Services Organizations
      • Vault Platform
      • ³Ô¹Ï±¬ÁÏ Connections Hub
    • Medical Suite
      • ³Ô¹Ï±¬ÁÏ Medical Suite
      • Operations
      • ³Ô¹Ï±¬ÁÏ PublicationsPlan, author, and manage publications
      • ³Ô¹Ï±¬ÁÏ MedCommsCentralize and scale medical content
      • ³Ô¹Ï±¬ÁÏ MedInquiryStreamline inquiry intake and fulfillment
      • Engagement
      • Medical CRMDrive high-impact scientific exchange
      • ³Ô¹Ï±¬ÁÏ Link Key PeopleGet deep data on KOLs and their ecosystems
      • ³Ô¹Ï±¬ÁÏ Link WorkflowManage KOL engagement workflows
      • Insights
      • ³Ô¹Ï±¬ÁÏ Link Medical InsightsAccelerate insights from capture to action
      • Measuring Medical Impact
      • Reimagine Medical Engagement
      • Learn About ³Ô¹Ï±¬ÁÏ Vault Platform
      • ³Ô¹Ï±¬ÁÏ Connections Hub
    • Commercial Solutions
      • ³Ô¹Ï±¬ÁÏ Commercial Solutions
      • Commercial Evidence?Transform field and digital interactions into actionable insights
      • Software
      • CRM SuiteCoordinated agentic engagement across channels
      • Campaign ManagerSynchronized sales and marketing
      • Events ManagementLive, virtual, and hybrid events
      • AlignTerritory, roster, and engagement planning
      • Patient CRMPatient support and engagement
      • ContentCompliant content at scale
      • Marketing AnalyticsCampaign measurement, targeting, and insights
      • Data Science and Analytics PlatformIntegrated commercial data for faster insights
      • Network MDMStandardized master data management
      • Data
      • Global Reference DataComplete HCP and HCO profiles
      • Global HCP DataHCP access data
      • Global Deep DataKOL profiles and key account data
      • U.S. Performance DataHigh-quality patient, prescriber, and national data
      • Services
      • Business ConsultingStrategic advisory services
    • Data Solutions
      • ³Ô¹Ï±¬ÁÏ Data Cloud
      • Global Reference Data
      • ³Ô¹Ï±¬ÁÏ OpenData CommercialComplete HCP and HCO profiles
      • ³Ô¹Ï±¬ÁÏ OpenData ClinicalAccurate site and investigator data
      • Global HCP Data
      • ³Ô¹Ï±¬ÁÏ HCP AccessHCP access data
      • Global Deep Data
      • ³Ô¹Ï±¬ÁÏ Link Key PeopleDeep data on KOLs
      • ³Ô¹Ï±¬ÁÏ Link Key AccountsDeep data on key accounts
      • U.S. Performance Data
      • ³Ô¹Ï±¬ÁÏ Compass PatientAnonymous patient longitudinal data
      • ³Ô¹Ï±¬ÁÏ Compass PrescriberHCP, HCO, and ZIP projected data
      • ³Ô¹Ï±¬ÁÏ Compass NationalState and national projected data
      • Services
      • ³Ô¹Ï±¬ÁÏ AnalyticsStrategic advisory services
    • Vault AI
      • Vault AI
      • Vault AI
      • Agentic AIBuilt into Vault Platform
      • AI AgentsDeploy standard and custom agents
      • Vault Platform
    • Research Site Solutions
    • Industries
      • Industries
      • Pharma & BiotechR&D, quality, medical, and commercial solutions
      • Consumer HealthSolutions from clinical to commercial
      • Animal HealthTailored applications for animal health
      • MedTechStreamline content and data management
  • Services
    • Services
    • Business Consulting
    • Analytics
    • ³Ô¹Ï±¬ÁÏ Digital Events
    • Partners
    • Services Partners
    • Product Partners
    • AI Partners
    • Content Partners
    • CRO Partners
    • Data Partners
  • Customers
  • Resources
  • Events
  • About ³Ô¹Ï±¬ÁÏ
    • About ³Ô¹Ï±¬ÁÏ
    • Leadership
    • Public Benefit Corporation
    • Corporate Citizenship
    • Diversity at ³Ô¹Ï±¬ÁÏ
    • Partners
    • Trust
    • Recent University Graduates
    • News
    • Announcements
    • Press Coverage
    • ³Ô¹Ï±¬ÁÏ Blog
    • Contact Us
  • Contact Us
  • ³Ô¹Ï±¬ÁÏ Logo
  • ³Ô¹Ï±¬ÁÏ
      Clinical
      Regulatory
      Safety
      Quality
      Medical
      Commercial
      Data
      Vault AI
      Research Sites
      Industries
      Demo Center
      VEEVA Development Cloud
      ³Ô¹Ï±¬ÁÏ Clinical Platform
      Clinical Operations
      ³Ô¹Ï±¬ÁÏ eTMF

      Stay inspection ready

      ³Ô¹Ï±¬ÁÏ CTMS

      Manage trials end-to-end

      ³Ô¹Ï±¬ÁÏ Payments

      Pay clinical research sites faster

      ³Ô¹Ï±¬ÁÏ Study Startup

      Accelerate site activation

      ³Ô¹Ï±¬ÁÏ RTSM

      Randomization and supply management

      ³Ô¹Ï±¬ÁÏ Site Connect

      Automate information sharing

      ³Ô¹Ï±¬ÁÏ Study Training

      Streamline and automate training

      ³Ô¹Ï±¬ÁÏ Disclosures

      Centralize clinical trial disclosures

      ³Ô¹Ï±¬ÁÏ OpenData Clinical

      Provide investigator and site data

      Clinical Data
      ³Ô¹Ï±¬ÁÏ EDC

      Collect and verify site data

      ³Ô¹Ï±¬ÁÏ DQS

      Aggregate and clean study data

      ³Ô¹Ï±¬ÁÏ eCOA

      Capture patient data

      Learn About the Patient Experience
      Learn About ³Ô¹Ï±¬ÁÏ Vault Platform
      ³Ô¹Ï±¬ÁÏ Connections Hub
      VEEVA Development Cloud
      ³Ô¹Ï±¬ÁÏ RIM
      ³Ô¹Ï±¬ÁÏ Registrations

      Track global registrations

      ³Ô¹Ï±¬ÁÏ Submissions

      Plan and manage submissions

      ³Ô¹Ï±¬ÁÏ Submissions Publishing

      Publish to health authorities

      ³Ô¹Ï±¬ÁÏ Submissions Archive

      Access submissions history

      Learn About ³Ô¹Ï±¬ÁÏ Vault Platform
      ³Ô¹Ï±¬ÁÏ Connections Hub
      VEEVA Development Cloud
      ³Ô¹Ï±¬ÁÏ Safety Suite
      ³Ô¹Ï±¬ÁÏ Safety

      Adverse Event management

      ³Ô¹Ï±¬ÁÏ SafetyDocs

      Manage safety content

      ³Ô¹Ï±¬ÁÏ Safety Workbench

      Advanced reporting and analysis

      ³Ô¹Ï±¬ÁÏ Safety Signal

      Signal detection and management

      Are you an emerging or clinical biotech? Learn More
      Learn About ³Ô¹Ï±¬ÁÏ Vault Platform
      ³Ô¹Ï±¬ÁÏ Connections Hub
      Are you a CRO? Learn more
      VEEVA QUALITY CLOUD
      Quality Assurance
      ³Ô¹Ï±¬ÁÏ QMS

      Manage all quality processes in one place

      ³Ô¹Ï±¬ÁÏ QualityDocs

      Gain control of GxP documents

      ³Ô¹Ï±¬ÁÏ Validation Management

      Manage and execute paperless validation

      ³Ô¹Ï±¬ÁÏ Batch Release

      Speed release decisions with confidence

      ³Ô¹Ï±¬ÁÏ Product Surveillance

      Simplify postmarket surveillance for medical devices

      ³Ô¹Ï±¬ÁÏ Station Manager

      Deliver right content to the right station

      Training
      ³Ô¹Ï±¬ÁÏ Training

      Ensure role-based qualification and compliance

      Quality Control
      ³Ô¹Ï±¬ÁÏ LIMS

      Optimize QC labs to increase efficiency

      Health and Safety
      ³Ô¹Ï±¬ÁÏ EHS

      Manage environmental, health, and safety processes

      Are you a contract services organization? Learn More
      Learn About ³Ô¹Ï±¬ÁÏ Vault Platform
      ³Ô¹Ï±¬ÁÏ Connections Hub
      ³Ô¹Ï±¬ÁÏ Medical Suite
      Operations
      ³Ô¹Ï±¬ÁÏ Publications

      Plan, author, and manage publications

      ³Ô¹Ï±¬ÁÏ MedComms

      Centralize and scale medical content

      ³Ô¹Ï±¬ÁÏ MedInquiry

      Streamline inquiry intake and fulfillment

      Insights
      ³Ô¹Ï±¬ÁÏ Link Medical Insights

      Accelerate insights from capture to action

      Engagement
      Medical CRM

      Drive high-impact scientific exchange

      ³Ô¹Ï±¬ÁÏ Link Key People

      Get deep data on KOLs and their ecosystems

      ³Ô¹Ï±¬ÁÏ Link Workflow

      Manage KOL engagement workflows

      Measuring Medical Impact
      Reimagine Medical Engagement
      Learn About ³Ô¹Ï±¬ÁÏ Vault Platform
      ³Ô¹Ï±¬ÁÏ Connections Hub
      VEEVA COMMERCIAL SOLUTIONS
      Commercial Evidence™

      Transform field and digital interactions into actionable insights

      Software
      CRM Suite

      Coordinated agentic engagement across channels

      Campaign Manager

      Synchronized sales and marketing

      Events Management

      Live, virtual, and hybrid events

      Align

      Territory, roster, and engagement planning

      Patient CRM

      Patient support and engagement

      Content

      Compliant content at scale

      Marketing Analytics

      Campaign measurement, targeting, and insights

      Data Science and Analytics Platform

      Integrated commercial data for faster insights

      Network MDM

      Standardized master data management

      Data
      Global Reference Data

      Complete HCP and HCO profiles

      Global HCP Data

      HCP access data

      Global Deep Data

      KOL profiles and key account data

      U.S. Performance Data

      Patient and prescriber data

      Services
      Business Consulting

      Strategic advisory services


      By Need
      Achieve Agentic Commercial
      Increase Omnichannel Impact
      Agentic AI for MLR
       
      Segmentation & Targeting
      DTC Advertising
      Launch Excellence
      VEEVA DATA CLOUD
      Global Reference Data
      ³Ô¹Ï±¬ÁÏ OpenData Commercial

      Complete HCP and HCO profiles

      ³Ô¹Ï±¬ÁÏ OpenData Clinical

      Accurate site and investigator data

      Global HCP Data
      ³Ô¹Ï±¬ÁÏ HCP Access

      HCP access data

      Global Deep Data
      ³Ô¹Ï±¬ÁÏ Link Key People

      Deep data on KOLs

      ³Ô¹Ï±¬ÁÏ Link Key Accounts

      Deep data on key accounts

      U.S. Performance Data
      ³Ô¹Ï±¬ÁÏ Compass Patient

      Anonymous patient longitudinal data

      ³Ô¹Ï±¬ÁÏ Compass Prescriber

      HCP, HCO, and ZIP projected data

      ³Ô¹Ï±¬ÁÏ Compass National

      State and national projected data

      Services
      ³Ô¹Ï±¬ÁÏ Analytics

      Strategic advisory services


      By Need
      Achieve Agentic Commercial
      Deepen Your Customer Insights
      Tailor Content at Scale
       
      Increase Omnichannel Impact
      Drive Launch Excellence

      By Need
      Segmentation & Targeting
      FOR VAULT PLATFORM
      & VEEVA APPLICATIONS
      Vault AI
      Agentic AI

      Built into Vault Platform

      AI Agents

      Deploy standard and custom agents

      Learn About ³Ô¹Ï±¬ÁÏ Vault Platform
      Industries
      Pharma & Biotech

      R&D, quality, medical, and commercial solutions

      Consumer Health

      Solutions from clinical to commercial

      Animal Health

      Tailored applications for animal health

      MedTech

      Streamline content and data management

      Demo Center
      AI (³Ô¹Ï±¬ÁÏ AI)

      Clinical Operations

      Clinical Data

      Regulatory

      Safety

      Development Cloud

      Quality

      Commercial

      Medical

      Data

  • Services
      Services
      Business Consulting
      Analytics
      ³Ô¹Ï±¬ÁÏ Digital Events
      Partners
      Services Partners
      Product Partners
      AI Partners
      Content Partners
      CRO Partners
      Data Partners
  • Customers
  • Resources
  • Events
  • About ³Ô¹Ï±¬ÁÏ
      About ³Ô¹Ï±¬ÁÏ
      Leadership
      Public Benefit Corporation
      Corporate Citizenship
      Diversity at ³Ô¹Ï±¬ÁÏ
      Partners
      Trust
      Recent University Graduates
      News
      Announcements
      Press Coverage
      ³Ô¹Ï±¬ÁÏ Blog
      Contact Us
Industry Report

³Ô¹Ï±¬ÁÏ Pulse Field Trends Report Q3 2022

HCP access rebounds to 60%, but not for everyone.

Download PDF
Table of Contents

NOVEMBER 2022

HCP Access Rebounds to 60%, But Not for Everyone

Sixty percent. That¡¯s the average percentage of accessible healthcare professionals (HCPs) in the U.S. across top specialties. Does that number surprise you?

Informed by anecdotal and limited data, there¡¯s a common belief that HCP access is much lower and hasn¡¯t returned to pre-pandemic levels.

Now with ³Ô¹Ï±¬ÁÏ Pulse¡ªthe largest-ever analysis of 600 million annual HCP-rep interactions globally across more than 80% of the industry¡ªwe have the full picture: HCP access is back, and more virtual. However, it¡¯s more selective than ever. And with the rapidly changing channel mix, field effectiveness also varies even more widely among companies.

Although access is not the same for everyone, there are clear steps companies can take to be more successful. Field teams must understand which HCPs are genuinely accessible, and which HCPs are selectively engaging with other companies. And, they must allocate their valuable¡ªyet limited¡ªfield resources accordingly, including rethinking targeting and channel mix to achieve the right reach.

Read on for our in-depth analysis of HCP access and recommended actions, and reach out to ³Ô¹Ï±¬ÁÏ Business Consulting to find out how we can help you use this industry data to help measure your access relative to the industry, improve your field execution, and achieve our shared vision for commercial excellence.

Thank you,

Dan Rizzo
Vice President, Business Consulting, ³Ô¹Ï±¬ÁÏ


PULSEINSIGHT

Access is back and includes video for 50% of accessible HCPs

Defining HCP access
In this report, HCP access is defined as an HCP¡¯s willingness to meet with reps, either in-person or via video.

Historically, HCP access has largely been measured by in-person meetings. But, even before the pandemic pushed HCP access to an all-time low of roughly 20%, historical estimates have shown a significant decline for more than a decade. Now, HCP access is back¡ªand perhaps even better than some pre-pandemic estimates¡ªbut in a different way.

³Ô¹Ï±¬ÁÏ Pulse data show that HCP access has rebounded to 60% across specialties. A closer look reveals that this engagement is increasingly virtual: of those accessible HCPs, more than 50% meet with reps via a hybrid mix of in-person and video channels.

Figure 1 I HCP Access Trends

There is also significant variation in access and channel usage by specialty (Figure 2). The specialties with the lowest access are psychiatry, internal medicine, and neurology. In contrast, the highest access levels are in immunology, diabetes, and dermatology. Interestingly, 78% of accessible oncologists engage via a mix of in-person and video vs. in-person alone, a wider gap than any other specialty.

This data shows that in-person meetings are no longer the sole indicator of HCP access. Investments made in omnichannel capabilities like video continue to yield results and can be a powerful differentiator in combination with in-person tactics.

Figure 2 I U.S. HCP Access by Specialty and Channel

KEYTAKEAWAY

Reevaluate how you measure HCP access beyond your own field organization and ensure you¡¯re using video to help expand your access.


PULSEINSIGHT

Video expands access and improves promotional response

3x

promotional response from video when added between in-person.

Companies with the highest level of access to HCPs leverage video as an additive channel, according to key findings from the previous ³Ô¹Ï±¬ÁÏ Pulse Field Trends Report. In addition, the report showed video has a three times greater promotional response when added between in-person meetings.

2.5x

increase in oncologist meetings with combined in-person and video

Interestingly, video is also connected to increased in-person meeting frequency. For example, oncologists who meet with reps in-person only average 4.5 meetings per month, while oncologists who engage via a mix of in-person and video average 11 meetings per month, including double the amount of in-person touch points (Figure 3).

Figure 3 I In-Person and Video Meetings vs. In-Person Meetings Alone in Oncology

KEYTAKEAWAY

Educate your field on the impact video can have on accelerating sales, build it into your call plans, and use video as an additive channel to in-person.


PULSEINSIGHT

Most accessible HCPs only meet with select companies

Although access is better than most companies think, there¡¯s a catch: access is not the same for everybody. Fifty percent of accessible HCPs are highly selective and limit their access to three or fewer biopharmas (Figure 4), and that access can vary greatly by specialty.

Figure 4 I Not All Access is Created Equal

Urology, psychiatry, internal medicine, and oncology are the most selective specialties. For example, most oncologists meet with three or fewer companies, and 30% of psychiatrists limit access to just one company (Figure 5). On the other hand, immunology, diabetes, and dermatology are the least selective. More than 70% of immunologists are accessible to four or more companies.

It is imperative for field teams to understand the true nature of target HCP access. Are they open to everyone, no one, or just a select few companies?

Figure 5 I U.S. HCP Selectivity, 30-Day Average

KEYTAKEAWAY

Understand if target HCPs are truly inaccessible vs. limiting their access to a select few.


PULSEINSIGHT

Some companies are more effective¡ªand efficient¡ªat reaching HCPs

Defining HCP reach
In this report, HCP reach is defined as a company¡¯s ability to engage an accessible HCP either in-person or via video.

In addition to disparities in access, wide gaps in HCP reach exist between companies as well. Companies with the strongest reach have on average three times the reach of their peers (Figure 6a) and, in some areas, the differences are even more drastic. For example, in diabetes, the company with the highest reach engages 63% of total HCPs vs. the weighted average of 11%. That means there¡¯s a wide gap between leading companies and the rest of the pack.

The data also demonstrates that some field forces are more efficient than others. For example, in the oncology space (Figure 6b), six companies with approximately the same reach had significantly different field sizes, ranging from more than 700 reps on the high end, to roughly 250 on the low end. This suggests that the ¡®more boots on the ground¡¯ approach is not the sole solution to improving reach.

Figure 6a I U.S. Access and Reach by Specialty

Figure 6b I Reach vs. Oncology Field Force Size

KEYTAKEAWAY

In addition to evaluating your access relative to your peers, benchmark field productivity to gauge efficiency levels.


PULSEINSIGHT

Digitally-enabled reps use content, time with HCPs more effectively

Getting access to the HCP is the first step. But how you use that time with the HCP is equally important. Our last report demonstrated how promotional success is driven by time with the customer and the effective use of content. Time with the customer through a blend of in-person and video channels signals trust. Content use signals effective and clear communication. Engagement through all other channels¡ªe.g., email, phone, chat¡ªare secondary support for digitally enabled reps who optimize for facetime with the customer.

"The last few years have pushed us to reevaluate our field force strategy and find better ways of maintaining successful HCP relationships. ³Ô¹Ï±¬ÁÏ Pulse proves that digitally-enabled reps create a better experience for customers, are more efficient in educating prescribers, and are better connected to our overall brand strategy through cross-channel engagement." Kate Greengrove, Head of Commercial Operations, GlaxoSmithKline

But not all companies are using their reach the same way. In an analysis of oncology, ³Ô¹Ï±¬ÁÏ Pulse and ³Ô¹Ï±¬ÁÏ Compass data shows that the most commercially successful field teams use their access more effectively than lagging companies, even when normalized for field force size and reach. What is it that makes these teams more effective?

The data show that these field teams:

³Ô¹Ï±¬ÁÏ Pulse and Compass, April 2022 - September 2022, companies with with similar field force size and reach

KEYTAKEAWAY

Maximize field productivity planning, reinforce the importance of content usage, and use video to help increase meetings between in-person discussions.


Three keys to improving field effectiveness

As you use this data to plan your field force strategy and execution, stay focused on these three key takeaways:

  1. Access is back, but in a different way. HCP access is now averaging 60% driven by in-person and video. ³Ô¹Ï±¬ÁÏ Pulse data gives the industry a reliable source to understand how HCPs are engaging across this channel mix.
  2. Access is more virtual and selective. Determine if target HCPs are truly inaccessible vs. limiting their access and compare HCP access to field force reach to reveal efficiency gaps and broaden channel strategies.
  3. Field force effectiveness varies greatly by company. Engage HCPs more effectively via a mix of in-person and video as well as sharing content more frequently to drive new treatment starts.

For more insights on how to use ³Ô¹Ï±¬ÁÏ Pulse data to benchmark your field effectiveness, reach out to us at businessconsulting@veeva.com.

Global and Regional Views

This section highlights global and regional engagement trends from ³Ô¹Ï±¬ÁÏ Pulse data between April to September 2022. ³Ô¹Ï±¬ÁÏ Pulse data is sourced from ³Ô¹Ï±¬ÁÏ¡¯s aggregated CRM activity dataset, inclusive of field engagement stats from all instances of ³Ô¹Ï±¬ÁÏ CRM globally.

Global trends

  1. Total activity across engagement channels decreased during July and August (Figure 7). In-person continues to be the most widely used channel (Figure 8), at 76% versus 15% email, 5% phone, 3% video, and 1% chat or text. In-person HCP engagement increased slightly quarter-to-quarter, from 73% to 76%, despite the slight decrease in total activity.
  2. The proportion of email activity decreased from 18% to 15%, as indicated by a decline in ³Ô¹Ï±¬ÁÏ CRM Approved Email volume (Figure 12).
  3. This quarter, content usage rates were on the rise. Content usage via ³Ô¹Ï±¬ÁÏ CRM Engage remained consistently high at 85%, while content utilization through other video platforms increased by 10% and 5% via in-person (Figure 13).
  4. Clear differences remain in the level and type of engagement between user types. As expected, sales reps had the highest productivity, but key account managers (KAMs) were most active via phone (three calls per user per week). Despite recording the lowest volume of activity, medical users had the highest proportion of video channel activity, with two calls per user per week (Figure 10).
  5. Differences also exist when comparing regional channel preferences. Most HCP interactions (91%) in China were in person, much greater than in any other major region (Figure 9). The Asia Pacific region had the most video calls (three per user per week) compared to only one per user per week in all other regions.

Figure 7 I Channel Mix Evolution

Figure 8 I Channel Mix

Global Field Team Activity

Weekly Activity Per User by Engagement Channel

Figure 9 I Activity by Region

Figure 10 I Activity by User Type

Figure 11 I Activity by Company Size

Global Field Team Activity

Weekly Activity Per User by Engagement Channel

Figure 12 I Approved Email Volume

Figure 13 I Content Usage by Channel

Figure 14 I Engage Meeting Duration

U.S. market trends

  1. The U.S. remained the most unchanged region since the last report, with a consistent channel mix (Figure 16).
  2. The proportion of digital interactions (email, phone, and video engagement) remained consistent since last quarter at 29% (Figure 16). Adoption of chat or text calls in the U.S. remained lower than in other regions, accounting for just 0.03% (Figure 16) or approximately 500 touchpoints weekly, versus approximately 20,000 in Asia Pacific, and 6,500 in Europe, even amid its seasonal slowdown.
  3. Content utilization in ³Ô¹Ï±¬ÁÏ Engage meetings remained at 80% (Figure 21), while the average ³Ô¹Ï±¬ÁÏ CRM Engage meeting duration in the U.S. remained the highest of any region at 18 minutes.
  4. Despite maintaining the volume of email delivered via ³Ô¹Ï±¬ÁÏ CRM Approved Email, open rates declined by 2% since June, ending the quarter at 28%, and click rates decreased by 1% (Figure 20).

Figure 15 I Channel Mix Evolution, U.S.

Figure 16 I Channel Mix, U.S.

U.S. Field Team Activity

Weekly Activity Per User by Engagement Channel

Figure 17 I Activity, U.S.

Figure 18 I Activity by User Type

Figure 19 I Activity by Company Size

U.S. Engagement Quality

Consolidation of Key Quality Metrics

Figure 20 I Approved Email Volume, U.S.

Figure 21 I Content Usage by Channel, U.S.

Figure 22 I Engage Meeting Duration, U.S.

Europe market trends

  1. The European region saw the most dramatic increase in content utilization during this time period. Content utilization in video meetings increased by 10%, while in-person content usage increased by 7% (Figure 29).
  2. Despite the nearly identical weekly total activity, France and the U.K. significantly differed in how the field engaged with customers. The in-person mix in France was more than double that in the U.K., with the U.K. filling the engagement gap through a higher mix of video and email. Video usage in the U.K. was the highest in Europe at three meetings per user per week.
  3. Medical users recorded one-third of the email volume compared to sales and KAM users (Figure 26).

Figure 23 I Channel Mix Evolution, Europe

Figure 24 I Channel Mix, Europe

Europe Field Team Activity

Weekly Activity Per User by Engagement Channel

Figure 25 I Activity by Country in Europe

Figure 26 I Activity by User Type

Figure 27 I Activity by Company Size

Europe Engagement Quality

Consolidation of Key Quality Metrics

Figure 28 I Approved Email Volume, Europe

Figure 29 I Content Usage by Channel, Europe

Figure 30 I Engage Meeting Duration, Europe

Asia Pacific market trends

  1. In-person engagement made up 77% of the channel mix in the Asia Pacific region (Figure 32) this quarter. The Asia Pacific region incorporated more chat or text messages into its channel mix than other regions, representing 2% of total activity (Figure 32).
  2. Content utilization remained very high, with usage greater than any other major region in each of the three channels (Figure 37). In-person content utilization saw the largest increase, reaching 59% by the end of the quarter.
  3. ³Ô¹Ï±¬ÁÏ Engage meeting duration (11 minutes) was also the lowest of all the major regions (Figure 38).
  4. India recorded the highest weekly total user activity, with 85 touchpoints per user per week. This was driven by in-person engagement, with 67 in-person touchpoints per week (Figure 33).

Figure 31 I Channel Mix Evolution, Asia Pacific

Figure 32 I Channel Mix, Asia Pacific

Asia Pacific Field Team Activity

Weekly Activity Per User by Engagement Channel

Figure 33 I Activity by Country, Asia Pacific

Figure 34 I Activity by User Type

Figure 35 I Activity by Company Size

Asia Pacific Engagement Quality

Consolidation of Key Quality Metrics

Figure 36 I Approved Email Volume, Asia Pacific

Figure 37 I Content Usage by Channel, Asia Pacific

Figure 38 I Engage Meeting Duration, Asia Pacific

Latin America market trends

  1. In Latin America, the volume of total weekly activity remained consistent throughout the quarter. Mirroring global trends, in-person was the preferred HCP engagement channel, accounting for 75% of the channel mix. Email interactions were the second most preferred engagement channel, responsible for 17% of the channel mix (Figure 40).
  2. Total user productivity was consistently high across all individual markets compared to other major regions, with all markets registering more than 50 touchpoints weekly per user. Countries with higher user productivity, such as Ecuador (67), had greater in-person engagements (52) compared to those with lower user productivity (Figure 41).
  3. Unique to Latin America, content usage increased across all meeting channels. This improvement was most significant in ³Ô¹Ï±¬ÁÏ CRM Engage meetings, where content usage increased to 91% (Figure 45).
  4. As expected, sales reps had the highest activity. However, in line with global trends, medical representatives recorded the highest proportion of activity (two calls per user per week) in the video channel (Figure 42).
  5. The volume of delivered ³Ô¹Ï±¬ÁÏ CRM Approved Email remained consistent throughout the quarter at approximately 150K weekly; however, open rates declined by 6% since April, ending at 40% by the end of the quarter (Figure 44).

Figure 39 I Channel Mix Evolution, Latin America

Figure 40 I Channel Mix, Latin America

Latin America Field Team Activity

Weekly Activity Per User by Engagement Channel

Figure 41 I Activity by Country, Latin America

Figure 42 I Activity by User Type

Figure 43 I Activity by Company Size

Latin America Engagement Quality

Consolidation of Key Quality Metrics

Figure 44 I Approved Email Volume, Latin America

Figure 45 I Content Usage by Channel, Latin America

Figure 46 I Engage Meeting Duration, Latin America

Appendix: Data Dictionary

Metric definitions

  • Channel Mix Evolution Over Time: Weekly ³Ô¹Ï±¬ÁÏ CRM activity volume broken down by the channel of engagement (in-person, phone, video, email, chat, or text)
  • Q2 Channel Mix: Total ³Ô¹Ï±¬ÁÏ CRM activity volume for 2Q22 broken down by engagement channel percentage
  • Weekly Activities Per User: The average weekly number of ³Ô¹Ï±¬ÁÏ CRM activities submitted per number of users active in ³Ô¹Ï±¬ÁÏ CRM
  • Approved Email Volume: Volume of approved emails sent via ³Ô¹Ï±¬ÁÏ CRM
  • Email Open Rate: Percentage of approved emails opened at least once out of all approved emails sent via ³Ô¹Ï±¬ÁÏ CRM
  • Email Click Rate: Percentage of approved emails clicked at least once out of all approved emails sent via ³Ô¹Ï±¬ÁÏ CRM
  • In-Person % Content Usage: Percentage of in-person engagements that leveraged content in ³Ô¹Ï±¬ÁÏ CRM
  • Video % Content Usage: Percentage of video engagements that leveraged content in ³Ô¹Ï±¬ÁÏ CRM
  • Engage Meeting % Content Usage: Percentage of Engage meetings that leveraged content in ³Ô¹Ï±¬ÁÏ CRM
  • Engage Meeting Duration: The average duration of Engage meetings in minutes

Engagement channel definitions

  • In-Person: Submitted Calls with a CRM Standard Metrics call channel value of ¡®in-person¡¯
  • Phone: Submitted Calls with a CRM Standard Metrics call channel value of ¡®phone¡¯
  • Video: ³Ô¹Ï±¬ÁÏ Engage Calls and Video Calls via other platforms that are then recorded as calls in ³Ô¹Ï±¬ÁÏ CRM with a Standard Metrics call channel value of ¡®video¡¯
  • Email: Approved Emails and Emails sent via other platforms that are then recorded as calls in ³Ô¹Ï±¬ÁÏ CRM with a Standard Metrics call channel value of ¡®email¡¯
  • Chat or Text: Submitted calls with a CRM Standard Metrics call channel value of ¡®chat or text¡¯

User type definitions

  • Sales: Users that have been classified with the ¡®Sales¡¯ value in the CRM Standard Metrics user type field
  • Key Account Manager: Users that have been classified with the ¡®Key Account Manager¡¯ value in the CRM Standard Metrics user type field
  • Medical: Users that have been classified with the ¡®medical¡¯ value in the CRM Standard Metrics user type field

Company size definitions

  • Top Global Pharma: ³Ô¹Ï±¬ÁÏ CRM customers included in the top 17 pharma companies based on global revenue
  • Rest of Industry: All other ³Ô¹Ï±¬ÁÏ CRM customers
  • Weighted Average: All companies based on access

Methodology

The ³Ô¹Ï±¬ÁÏ Pulse Field Trends Report is a quarterly industry benchmark for global and regional healthcare professional (HCP) engagement across the life sciences industry. The report is based on proprietary ³Ô¹Ï±¬ÁÏ Pulse data and insights from field engagement activities of more than 80% of all industry representatives worldwide (Asia Pacific, Europe, Latin America, and the United States). ³Ô¹Ï±¬ÁÏ CRM Standard Metrics¡ªnow used industrywide¡ªprovides the basis for consistent collection and measurement of engagement KPIs including channel mix and productivity across regions, roles, and market segments. The findings are based on approximately 235 million global field representative activities captured in ³Ô¹Ï±¬ÁÏ CRM and ³Ô¹Ï±¬ÁÏ CRM Engage, as well as 42+ billion prescription (Rx) and medical (Mx) records captured in ³Ô¹Ï±¬ÁÏ Compass, a U.S.-based longitudinal patient claims data set, between April and September 2022.

The ³Ô¹Ï±¬ÁÏ Pulse Field Trends Report delivers insights that inform the industry and help field teams align their strategy to key market trends for improved commercial success. The global ³Ô¹Ï±¬ÁÏ Business Consulting team also helps customers inform their strategies using industry benchmarking with ³Ô¹Ï±¬ÁÏ Pulse data.

Let's Partner

Interested in learning more about
how ³Ô¹Ï±¬ÁÏ can help?

Contact Us Download PDF
Join the Conversation in ³Ô¹Ï±¬ÁÏ Connect

Where customers and ³Ô¹Ï±¬ÁÏ product leaders share information and ideas

³Ô¹Ï±¬ÁÏ Logo

Software, AI, Data, and Consulting for the Global Life Sciences Industry

? Copyright 2026 ³Ô¹Ï±¬ÁÏ Systems

Global Headquarters

Follow Us on Social

Demo Center Contact ³Ô¹Ï±¬ÁÏ

Solutions

  • Clinical
  • Regulatory
  • Safety
  • Quality
  • Medical
  • Commercial
  • Industry Segments

Services

  • Business Consulting

Partners

  • Service Partners
  • Product Partners
  • AI Partners
  • Content Partners
  • CRO Partners
  • Data Partners

Resources

  • Customer Stories
  • Resource Center
  • Events
  • News & Press
  • Blog

About ³Ô¹Ï±¬ÁÏ

  • Leadership
  • Public Benefit Corporation
  • Corporate Citizenship
  • Diversity at ³Ô¹Ï±¬ÁÏ
  • Trust

Global Headquarters

Follow Us on Social

Do Not Sell or Share My Personal Information Privacy Notice Terms Site Map